Pradaxa litigation moves forward

During these unprecedented times, Clark, Perdue, & List Co, LPA is here to fully support your needs in a timely and safe manner. COVID-19 should not affect your ability to investigate a personal injury case. We currently remain open and are still accepting new cases. With your safety top of mind, we are scheduling all meetings via telephone or video conference at this time.

Following an initial hearing on October 3, 2012, the Honorable David R. Herndon issued a case management plan for the pending Pradaxa pharmaceutical lawsuits that have been consolidated in a multi-district litigation (“MDL”) venued in the U.S. District Court for the Southern District of Illinois.  As part of his order, Judge Herndon set trial dates for five “bellweather” cases commencing August 11, 2014.

Over 100 Pradaxa lawsuits have been transferred to the MDL and many more are expected.  At the core of the allegations relating to Pradaxa, a blood thinner manufactured by Boehringer Ingelheim, is the fact that there is no antidote for bleeding caused by Pradaxa.  Unlike its chief competitor, The lawsuits that have been filed claim that warnings concerning the lack of an antidote were inadequate and that the lack of an antidote is a “dramatic departure from all other blood thinners.”

As many as 542 deaths associated with Pradaxa have been reported to the U.S. Food and Drug Administration.

Clark, Perdue & List is currently handling these claims.  For more information, contact the Ohio Pradaxa lawyers at Clark, Perdue & List.

Source: Injury Lawyer News, “Despite growing Pradaxa litigation, no sign of a Pradaxa recall,” Tracy Ray, October 6, 2012.